Publications

Letter Epublish

PubMed: 40756255 DOI: 10.2147/CEOR.S550970

Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma [Letter].

Clinicoecon Outcomes Res 17:535-536

Authors: Niodita Gupta-Werner, Joseph Goble, Mary Slavcev

Affiliations

  • Johnson & Johnson, Horsham, PA, USA.

MeSH

Multiple Myeloma, Therapeutics